According to the Financial Associated Press (Shanghai, researcher Yao Hui), the data shows that the total net inflow of northbound funds into A shares this week was 29.197 billion yuan, and the total net purchase in January was 42.846 billion yuan.
From the perspective of the transaction and capital flow of the top ten active stocks of northbound funds in the past 7 days, China Merchants Bank ranked first with net purchases of 4.9 billion yuan, Ping An of China and Kweichow Moutai ranked second with net purchases of 2.5 billion yuan and 2.1 billion yuan respectively. three. In the past 7 days, China CDF ranked first with a net sales of 1.1 billion yuan in northbound funds, while Aier Ophthalmology and Hengrui Medicine ranked second and third with a net sales of 1.1 billion and 800 million yuan respectively.
From the perspective of the transaction and capital flow of the top ten active stocks of northbound funds in the past month, China Merchants Bank ranked first in net purchases of 5.5 billion yuan, and China Ping An and Guodian NARI ranked first with net purchases of 3.6 billion yuan and 2.6 billion yuan respectively. Two or three. In the past month, Luxshare Precision has topped the list with a net sales of 2.7 billion yuan in northbound funds, while Aier Eye and China CDFG ranked second and third with a net sales of 2.3 billion yuan and 1.8 billion yuan respectively.
Judging from the list of stocks with the highest surging ratio of northbound funds this week, there are 14 stocks with a surging ratio of more than 1%, and 7 stocks with a surging ratio of more than 1.4%, namely Yongtai Technology, Yirui Biology, and Jinlei Shares , Feikai Materials, Hongri Pharmaceutical, Tuowei Information and AVIC Electromechanical, the specific list is as follows:
Yongtai Technology ranked first in the proportion of northbound funds Masukura this week, reaching 2.10%. The research report released by Su Chen and others of Zhongtai Securities on October 18, 2021 pointed out that Yongtai Technology has entered the leading enterprises to prove its product strength. The company is currently producing and planning 6F production capacity of 28,000 tons, VC30,000 tons, FEC8000 tons, LiFSI20500 It is the third-party supplier with the largest production capacity and the most complete categories of electrolyte solutes in China. It will benefit from the shortage of 6F and VC in the short term, and it is expected that the long-term entry into C matching will lock in long-term profits through the cycle.
Yirui Biology ranked second in the northbound fund Masukura ratio this week, reaching 1.58%. Yirui Bio announced on January 19 that it expects a net profit of 220 million to 260 million yuan in 2021, a year-on-year increase of 236.16% to 297.28%. The company’s new crown antigen detection reagent semi-finished products and supporting solutions The order and revenue have increased.
Jinlei shares ranked third in the northbound capital Masukura ratio this week, reaching 1.55%. The research report released by Shanghai Securities Kaiwen on November 4, 2021 pointed out that Jinlei is the leader of the domestic wind power spindle. Benefiting from the rapid development of the wind power industry and the restructuring of the industry valuation system, the company’s market share has gradually increased.
Feikai Materials ranked fourth in the proportion of northbound funds Masukura this week, reaching 1.51%. A research report released by Zhuang Tingzhou and others from Huatai Securities on January 1 pointed out that the categories of screen display materials and light-curing materials of Feikai materials have expanded, and the volume of pharmaceutical intermediates has increased. The convertible bond fundraising and investment projects have been steadily advanced, and the product structure has been continuously enriched. In the future, pharmaceutical intermediates, semiconductor materials, display materials and coatings will flourish, driving continuous growth in performance.
Red Sun Pharmaceutical ranked fifth in the proportion of northbound funds Masukura this week, reaching 1.43%. The research report released by Dongxing Securities Hu Boxin and others on January 20 pointed out that the formula granule business of Hongri Pharmaceutical has benefited from the release of sales channels and prescription rights under the implementation of the national standard, and the market substitution of Chinese patent medicines and Chinese herbal decoction pieces. Good price increase expectations, optimistic about the rapid growth of the company’s formula granule business, and the medical device and finished drug sectors are also promising in the future.
Tuowei Information ranked sixth in the northbound capital Masukura ratio this week, reaching 1.42%. On September 18 last year, the company replied on Interactive Easy that it will continue to pay attention to the development of cutting-edge technologies, with 5G, AI, big data, Internet of Things, and edge computing as the core, actively explore market demand, promote industrial upgrading, and help the digital economy. The research report released by Lu Wei of Essence Securities on October 15, 2021 pointed out that Tuowei Information joined the Open Atomic Open Source Foundation and became a member of the Open Harmony project group. The application scenario is the vanguard of landing.
Fusion Mediaor anyFusion MediaThe parties concerned do not accept any responsibility for loss or damage arising from reliance on the data, quotes, charts and buy/sell signals contained in this website. Please fully understand the risks and costs associated with trading in financial markets, one of the riskiest forms of investing. The English version of this Agreement is the primary version. If there is any discrepancy between the English version and the Chinese version, the English version shall prevail.